Фармакологический профиль антагониста aLa-ааренорецепторов силодозина

Автор: Michel Martin C.

Журнал: Экспериментальная и клиническая урология @ecuro

Статья в выпуске: 1, 2012 года.

Бесплатный доступ

Антагонисты al-адренорецепторов, фармакология, селективность, симптомы нижних мочевых путей, доброкачественная гиперплазия предстательной железы

Короткий адрес: https://sciup.org/142188287

IDR: 142188287

Список литературы Фармакологический профиль антагониста aLa-ааренорецепторов силодозина

Roehrborn C.G., Mc Connel J., Barry M.J. et al. Guideline on the Management of Benign Prostatic Hypertrophy. А11А website: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/bph-management/preface_toc.pdf.
Milani S., Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest updated on ü1-adrenoceptor antagonists//BJU Int. 2005. Vol. 95, Suppl 4. P. 29-36.
van Dijk M.M., de la Rosette JJMCH, Michel M.C. Tamsulosin -modifi ed-release and oral-controlled absorption system formulation in the treatment of benign prostatic hyperplasia//Therapy. 2006. Vol. 3. P. 237-246.
Nickel J.C., Sander S., Moon T.D. А-meta-analysis of the vascular-related safety profile and efficacy of а-adrenergic blockers for symptoms related to benign prostatic hyperplasia//Int J Clin Pract. 2008. Vol. 62. P. 1547-1559.
Michel M.C., Vrydag W. а1-а2-and ß-Adrenoceptors in the urinary bladder, urethra and prostate//Br J Pharmacol. 2006. Vol. 147. P. 88-119.
Guimaraes S., Moura D. Vascular adrenoceptors: an update//Pharmacol Rev. 2001. Vol. 53. P. 319-356.
Rudner X.L., Berkowitz D.E., Booth J.V., Funk B.L., Cozart K.L., D,Amico E.B., El-Moalem H., Page S.O., Richardson C.D., Winters B., Marucci L., Schwinn D.A.l. Subtype specifi c regulation of human vascular ü1-adrenergic receptors by vessel bed and age//Circulation. 1999. Vol. 100. P. 2336-2243.
Michel M.C., Kenny B.A., Schwinn D.A. Classifi cation of ü1-adrenoceptor subtypes//Naunyn-Schmiedeberg's Arch Pharmacol. 1995. Vol. 352. P. 1-10.
Shibata K., Foglar R., Horie K., Obika K., Sakamoto A., Ogawa S., Tsujimoto G. KMD-3213, a novel, potent, ü1A-adrenoceptor-selective antagonist: characterization using recombinant human ü1-adrenoceptors and native tissues//Mol Pharmacol. 1995. Vol. 48, № 2. P. 250-258.
Murata S., Taniguchi T., Muramatsu I. Pharmacological analysis of the novel, selective ü1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand//Br J Pharmacol.1999. Vol. 127. P. 19-26.
Piao H., Taniguchi T., Nakamura S. et al. Cloning of rabbit a1b-adrenoceptor and pharmacological comparison of а1А-, ü1B-and аШ-adrenoceptors in the rabbit//Eur J Pharmacol. 2000. Vol. 396. P. 9-17.
Tatemichi S., Kobayashi K., Maezawa A., Kobayashi M., Yamazaki Y., Shibata N. ü1-Adrenoceptor subtype selectivity and organ specifi city of silodosin (KMD-3213)//Yakugaku Zasshi. 2006. Vol. 126. P. 209-216.
Nakamura S., Taniguchi T., Suzuki F., Akagi Y., Muramatsu I. Evaluation of ü1-adrenoceptors in the rabbit iris: pharmacological characterization and expression of mRNA//Br J Pharmacol. 1999. Vol. 127. P. 1367-1374.
Ohmi K., Shinoura H., Nakayama Y., Goda N., Tsujimoto G. Characterization of ü1-adrenoceptors expressed in a novel vascular smooth muscle cell line cloned from p53 knockout mice, P53LMAC01 (AC01) cells//Br J Pharmacol. 1999. Vol. 127. P. 756762.
Murata S., Taniguchi T., Takahashi M., Okada K., Akiyama K., Muramatsu I. Tissue selectivity of KMD-3213, an ü1-adrenoceptor antagonist, in human prostate and vasculature//J Urol. 2000. Vol. 164. P. 578-583.
Tanaka T., Zhang L., Suzuki F., Muramatsu I. Alpha-1 adrenoceptors: evaluation of receptor subtype-binding kinetics in intact arterial tissues and comparison with membrane binding//Br J Pharmacol. 2004. Vol. 141. P. 468-476.
Morishima S., Tanaka T., Yamamoto H., Suzuki F., Akino H., Yokoyama O., Muramatsu I. Identification of Ü-1L and ü-1A-adrenoceptors in human prostate by tissue segment binding//J Urol. 2007. Vol. 177. P. 377-381.
Yamada S., Okura T., Kimura R. In vivo demonstration of ü1A-adrenoceptor subtype selectivity of KMD-3213 in rat tissues//J Pharmacol Exp Ther. 2001. Vol. 296. P. 160167.
Morishima S., Suzuki F., Yoshiki H.G. et al. Identification of the a1Ladrenoceptor in rat cerebral cortex and possible relationship between ü1L-and ü1A-adrenoceptors//Br J Pharmacol. 2008. Vol. 153. P. 1485-1494.
Morishima S., Suzuki F., Nishimune A., Yoshiki H., Akino H., Yokoyama O., Muramatsu I. Visualization and tissue distribution of a1L-adrenoceptor in human prostate by the fluorescently labeled ligand Alexa-488-silodosin//J Urol. 2010. Vol. 183. P. 812-819.
Yamada S., Ohkura T., Kimura R., Kawabe K. In vivo receptor binding of novel ü1-adrenoceptor antagonists for treatment of benign prostatic hyperplasia//Life Sci. 1998. Vol. 62. P. 1585-1589.
Suzuki F., Taniguchi T., Takauji R., Murata S., Muramatsu I. Splice isoforms of а1А-adrenoceptor in rabbit//Br J Pharmacol. 2000. Vol. 129. P. 1569-1576.
YAmagishi R., Akiyama K., Nakamura S., Hora M., Masuda N., Matsuzawa A., Murata S., Ujiie A., Kurashina Y., Iizuka K., Kitazawa M. Amagishi R., Akiyama K., Nakamura S., Effect of KMD-3213, an ü1Aadrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta//Eur J Pharmacol. 1996. Vol. 315. P. 73-79.
Tatemichi S., Tomiyama Y., Maruyama I., Kobayashi S., Kobayashi K., Maezawa A., Kobayashi M., Yamazaki Y., Shibata N. Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia//Neurourol Urodyn. 2006. Vol. 25. P. 792-799.
Moriyama N., Nasu K., Takeuchi T., Akiyama K., Murata S., Nishimatsu H., Yano J., Tsujimoto G., Kawabe K. Quantification and distribution of ü1-adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions//Br J Pharmacol. 1997. Vol. 122. P. 1009-1014.
Moriyama N., Akiyama K., Murata S., Taniguchi J., Ishida N., Yamazaki S., Kawabe K. KMD-3213, a novel ü1A-adrenoceptor antagonist, potently inhibits the functional ü1-adrenoceptor in human prostate//Eur J Pharmacol. 1997. Vol. 331. P. 39-42.
Autelitano D.J., Woodcock E.A. Selective activation of ü1A-adrenergic receptors in neonatal cardiac myocytes is sufficient to cause hypertrophy and differential regulation of ü1-adrenergic receptor subtype mRNAs//J Mol Cell Cardiol. 1998. Vol. 30. P. 15151523.
Zhu J., Taniguchi T., Takauji R., Suzuki F., Tanaka T., Muramatsu I. Inverse agonism and neutral antagonism at a constitutively active alpha-1a adrenoceptor//Br J Pharmacol. 2000. Vol. 131. P. 5460-552.
Hein P., Goepel M., Cotecchia S., Michel M.C. A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster ü1B-adrenoceptors//Naunyn-Schmiedeberg's Arch Pharmacol. 2001. Vol. 363. P. 34-39.
Zhang L., Taniguchi T., Tanaka T., Shinozuka K., Kunitomo M., Nishiyama M., Kamata K., Muramatsu I. Alpha-1 adrenoceptor upregulation induced by prazosin but not KMD-3213 or reserpine in rats//Br J Pharmacol. 2002. Vol. 135. P. 1757-1764.
Tatemichi S., Akiyama K., Kobayashi M., Yamazaki Y., Yokoyama O., Uruno T. A selective ü1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia//J Urol. 2006. Vol. 176.P. 1236-1241.
Yazaki Y., Aikawa K., Ogawa S. et al. A selective ü1A-adrenoceptor antagonist improves detrusor overactivity secondary to bladder outlet obstruction through the inhibition of the afferent activation in the rat.//Neurourol Urodyn. 2008. Vol. 27. P. 610-611.
Marks L.S., Gittelman M.C., Hill L.A., Volinn W., Hoel G. Rapid efficacy of the highly selective ü1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies//J Urol. 2009. Vol. 181. P. 2634-2640.
Yokoyama O., Ito H., Aoki Y., Oyama N., Miwa Y., Akino H. Selective ü1A-blocker improves bladder storage function in rats via suppression of C-fiber afferent activity//World J Urol. In press. DOI 10.1007/s00345-009r-r0481-2.
Akiyama K., Hora M., Tatemichi S., Masuda N., Nakamura S., Yamagishi R., Kitazawa M. KMD-3213, a uroselective and longacting ü1A-adrenoceptor antagonist, tested in a novel rat model//J Pharmacol. Exp Ther. 1999. Vol. 291. P. 81-91.
Tomiyama Y., Tatemichi S., Tadachi M., Kobayashi S., Hayashi M., Kobayashi M., Yamazaki Y., Shibata N. Effect of silodosin on intraurethral pressure increase induced by hypogastric nerve stimulation in dogs with benign prostatic hyperplasia//Yakugaku Zasshi. 2006. Vol. 126. P. 225-230.
Akiyama K., Noto H., Nishizawa O., Sugaya K., Yamagishi R., Kitazawa M., Tsuchida S. Effect of KMD-3213, an a1Aadrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs//Int J Urol. 2001. Vol. 8. P. 177-183.
Tatemichi S., Kiguchi S., Kobayashi M., Yamazaki Y., Shibata N., Uruno T. Cardiovascular effects of the selective ü1A-adrenoceptor antagonist silodosin (KMD-3123), a drug for the treatment of voiding dysfunction//Arzneimittelforschung. 2006. Vol. 56. P. 682-687.
Akiyama K., Hora M., Yamagishi R., Kitazawa M. Effects of KMD-3213, a uroselective ü1A-adrenoceptor antagonist, on the tilt-induced blood pressure response in normotensive rats//Jpn J Pharmacol. 2002. Vol. 90. P. 131-137.
van Dijk M.M., de la Rosette JJMCH, Michel M.C. Effects of ü1-adrenoceptor antagonistsonmale sexual function//Drugs. 2006. Vol. 66. P. 287-301.
Nagai A, Hara R, Yokoyama T, Jo Y, Fujii T, Miyaji Y. Ejaculatory dysfunction caused by the new ü1-blocker silodosin: a preliminary study to analyze human ejaculation using color Doppler ultrasonography.//Int J Urol. 2008. Vol. 15. P. 915-918.
Kawabe K, YoshidaM, HommaY Silodosin, a new ü1A-adrenoceptor selective antagonist for treating benign prostatic hyperplasia: a results of a phase III randomized, placebocontrolled, double-blind study in Japanese men.//BJU Int. 2006. Vol. 98. P. 1019-1024.
Speakman M.J., Snijder R.J., Anthonijs G., Doyle C.A. Patients on tamsulosin experiencing abnormal ejaculation choose to remain longer in clinical trials and have slightly better improvement in symptom score than other patients. Abstract.//J Urol. 2003. Vol. 169. P. 334.
Roehrborn C.G., Lepor H., Kaplan S.A. Retrograde enaculation induced by silodosin is the result of relaxation of smooth musculature in the male urogenital tracts and is associated with greater urodynamic and symptomatic improvements in men LUTS secondary to BPH. Abstract//J Urol. 2009. Vol. 181, Suppl. P. 694.
Chang D.F., Campbell J.R. Intraoperative floppy iris syndrome associated with tamsulosin//J Cataract Refract Surg. 2005. Vol. 31. P. 664-673.
Watanabe M, Ohtake A, Yuyama H, et al. Effects of ü1-adrenoceptor antagonists on pupil diameter and intraurethral pressure in rabbits.//Jpn Pharmacol Ther. 2006. Vol. 34. P. 653-661.
Michel M.C. The forefront of novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: a-blockers in the treatment of male voiding dysfunc-tion-how do they work and why do they differ in tolerability?//J Pharmacol Sci. 2010. Vol. 112. P. 151-157.
Okura T., Yamada S., Abe Y., Kimura R. Selective and sustained occupancy of prostatic ü1-adrenoceptors by oral administration of KMD-3213 and its plasma concentration in rats//J Pharm Pharmacol. 2002. Vol. 54. P. 975-982.
Akiyama K., Tatemichi S., Katayama S., Nakajima M., Oki T., Okura T., Yamada S., Kimura R. Relationship between prostatic ü1-adrenoceptor binding and reduction in intraurethral pressure following continuous infusion of KMD-3213 in rats//Pharmacology. 2002. Vol. 64. P. 140-147.
Franco-Salinas G., de la Rosette JJMCH, Michel M.C. Pharmacokinetics and pharmacodynamics of tamsulosin in its modifi edrelease and oral-controlled absorption system formulations//Clin Pharmacokin. 2010. Vol. 49. P. 177-188.
Shimizu T., Miyashita I., Matsubara Y., Ikeda M., Yamaguchi M. Pharmacokinetic profile of silodosin in clinical practice//Yakugaku Zasshi. 2006. Vol. 26. P. 257-263.

Еще

Статья